Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;20(2):79-80.
doi: 10.1038/s41575-022-00738-z.

Improving IBD outcomes in the era of many treatment options

Taku Kobayashi  1 , Toshifumi Hibi  2
Affiliations

Improving IBD outcomes in the era of many treatment options

Taku Kobayashi et al. Nat Rev Gastroenterol Hepatol. 2023 Feb.

Erratum in

Abstract

Key studies published in 2022 highlight the emergence of several novel drugs for inflammatory bowel disease. Head-to-head trials and network meta-analyses have also been conducted to identify the sequencing of these treatments, but we still have a long way to go to achieve personalized medicine.

PubMed Disclaimer

Conflict of interest statement

T.K. has received lecture fees from Abbie GK, Activaid, Alfresa Pharma, Janssen Pharmaceutical, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Pfizer Japan, Takeda Pharmaceutical, Thermo Fisher Diagnostics and Zeria Pharmaceutical; research grants from Abbvie GK, Activaid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JMDC, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical; scholarship contributions from Mitsubishi Tanabe Pharma, Nippon Kayaku and Zeria Pharmaceutical; study group sponsorship by Abbvie GK, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings and Zeria Pharmaceutical; and advisory or consultancy fees from Abbie GK, Activaid, Alfresa Pharma, EA Pharma, Janssen Pharmaceutical, KISSEI Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical. T.H. has received lecture fees from Aspen Japan, Janssen, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer and Takeda Pharmaceutical; research grants from AbbVie GK, Activaid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JMDC, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical; scholarship contributions from Mitsubishi Tanabe Pharma, Nippon Kayaku and Zeria Pharmaceutical; and study group sponsorship from AbbVie GK, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings and Zeria Pharmaceutical.

Figures

Fig. 1
Fig. 1. Mechanism of action of immunomodulatory drugs in inflammatory bowel disease.
Drugs are shown in blue boxes. JAK, Janus kinase; S1P, sphingosine 1-phosphate; TH cell, T helper cell; TNF, tumour necrosis factor.
See this image and copyright information in PMC

References

    1. D’Haens G, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015–2030. doi: 10.1016/S0140-6736(22)00467-6. - DOI - PubMed
    1. Ferrante M, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031–2046. doi: 10.1016/S0140-6736(22)00466-4. - DOI - PubMed
    1. Sandborn WJ, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162:1650–1664.e8. doi: 10.1053/j.gastro.2022.01.047. - DOI - PubMed
    1. D’Heans G, et al. OP26 efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. J. Crohns Colitis. 2022;16(Suppl. 1):i028–i029. doi: 10.1093/ecco-jcc/jjab232.025. - DOI - PMC - PubMed
    1. Danese S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113–2128. doi: 10.1016/S0140-6736(22)00581-5. - DOI - PubMed

MeSH terms